12 August 2024
Abingdon Health plc
("Abingdon", the "Group", or the "Company")
Result of General Meeting and Total
Voting Rights
Abingdon (AIM:ABDX), a leading
international lateral flow contract development and manufacturing
organisation, is pleased to announce that, at the General Meeting
held earlier today, all resolutions as set out in its Notice of
General Meeting dated 24 July 2024 were duly
passed.
Capitalised terms used but not otherwise defined
in this announcement shall have the meanings given to them in the
Company's announcement made at 4:51 p.m. on 24 July
2024, unless the context requires otherwise.
Admission and Total Voting
Rights
Following the General Meeting, the Company will
allot and issue 53,589,741 Fundraising Shares.
Application has been made to the London
Stock Exchange for admission of the Fundraising Shares to
trading on AIM. It is expected that Admission will become effective
and dealings in the Fundraising Shares will commence on AIM
at 8.00 a.m. on or around the 14 August
2024. The Fundraising Shares will rank pari passu in all
respects with existing ordinary shares of 2.5
pence each.
Following Admission, the total number of shares
in the capital of the Company in issue with voting rights will be
189,523,153 ordinary shares of 2.5 pence each. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in,
Abingdon under the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules.
Result of the meeting
Details of the results of the voting (which was
undertaken by way of a poll vote) at the General Meeting are set
out below. Resolution 1 was proposed and passed as an ordinary
resolution and resolution 2 was proposed and passed as a special
resolution.
|
|
For
|
Against
|
|
|
Votes
|
% of votes cast
|
Votes
|
% of votes cast
|
|
1. Authority to Allot Shares
|
60,896,201
|
99.85%
|
92,916
|
0.15%
|
|
2. Disapply the pre-emption rights provisions of
section 561 of the Companies Act 2006 in respect of the allotment
of the Consideration Shares, the Further Consideration Shares, the
Placing Shares and the Retail Offer Shares.
|
60,886,201
|
99.83%
|
101,448
|
0.17%
|
The passing of the Resolutions is one of the
conditions to completion of the Fundraising, and as a result of the
votes cast in their favour, that particular condition has been
satisfied.
For further
enquiries:
|
Abingdon Health
plc
|
www.abingdonhealth.com/investors/
|
|
Chris Yates, Chief Executive
Officer
|
|
|
Chris Hand, Non-Executive
Chairman
|
|
|
Zeus Capital
Limited (Sole Broker and Nominated Adviser)
|
Tel: +44 (0) 20 7220 1666
|
|
Chris Fielding / Isaac Hooper (Corporate
Finance)
|
|
|
Fraser Marshall (Corporate Broking)
|
|
|
|
|
|
|
|
|
|
|
| |
The person responsible for arranging the release
of this announcement on behalf of the Company is Chris Yates, Chief
Executive Officer of the Company.
About Abingdon Health plc
Abingdon Health is a leading lateral flow
contract development and manufacturing organisation ("CDMO")
offering its services to an international customer base across
industry sectors that include clinical, animal health, plant
health, and environmental testing. Abingdon has the internal
capabilities to take projects from initial concept through to
routine and large-scale manufacturing; from "idea to commercial
success".
The Company's CDMO division offers product
development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays
or transfer existing laboratory-based assays to a lateral flow
format. Abingdon aims to support the increase in need for rapid
results across many industries and locations; and produces lateral
flow tests in areas such as infectious disease and clinical
testing, including companion diagnostics, animal health and
environmental testing. Faster access to results allows for rapid
decision making and targeted intervention; and can support better
outcomes.
Abingdon 's Abingdon Simply Test® range of
self-tests is an e-commerce platform that offers a range of
self-tests to empowers consumers to manage their own health and
wellbeing. The Abingdon Simply
Test® e-commerce site offers
consumers a range of information to support them in making informed
decisions on the tests available. In addition, the site provides
Abingdon's contract services customers with a potential route to
market for self-tests. The Abingdon Simply Test® range is also sold
through international distributors and through other channels in
the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon is headquartered in
York, England.
For more
information visit: www.abingdonhealth.com